A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
|Articles|May 28, 2020
FDA Grants Emergency Use to Quest Diagnostics COVID-19 Self-Collection Kit
Author(s)Kevin Kunzmann
Collected specimens can be tested with the Quest Diagnostics SARS-CoV-2 RT-PCR test to have received EUA from the FDA earlier in March.
Advertisement
The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Quest Diagnostics Self-Collection Kit for
The EUA granted users the ability to self-collect nasal specimens at either home or in a healthcare setting, to be shipped overnight at room temperature to certified testing sites.
More notably, collected specimens can be tested with the Quest Diagnostics SARS-CoV-2 RT-PCR test to have received EUA from the FDA earlier in March. The use of RT-PCR testing aids diagnosing infection of the COVID-19 virus.
Quest Diagnostics now intends to make the kits available through several channels including for patient care and healthcare workers, as well as for states and organizations aiming to bolster return-to-work testing programs. Eventually, the kits could be made available to other employers or individual users.
“The company will prioritize healthcare workers, first responders, law enforcement personnel and others critical to pandemic response to ensure they have timely access to the kit,” they stated. “The company expects to have more than a half-million kits available by the end of June, with plans to make additional kits available on an ongoing basis.”
The kit aims to improve on more invasive, “uncomfortable” methods of COVID-19 testing made available in the last months, while contributing to the currently limited supply of testing materials being made available in the US currently.
"We plan to utilize this device with a range of populations, from state-run programs and employers to healthcare providers and individuals," Jay G. Wohlgemuth, MD, senior vice president and chief medical officer of Quest Diagnostics, said in a statement. "Our scientists at our advanced diagnostics laboratory in San Juan Capistrano, California developed the technology, which has been validated in real-world studies."
Advertisement
Related to this article
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Advertisement
Advertisement